title: Perspectives in the treatment of reversible airway obstruction.
abstract: The pharmacological therapy of asthmatic syndromes is based essentially on the programmed use of disodium cromoglycate, beta-2-stimulants, antimuscarinics, theophyllines and corticosteroids. However, the continual progress being made in pathogenesis and pharmacology suggests, to an ever-increasing extent, the application of new therapeutic approaches for these diseases, some of which are fairly interesting from a speculative point of view although they are as yet of limited practical value. Calcium antagonists and alpha-blockers have a mild anti-reactive effect but this is not sufficiently potent to justify use of these products in the treatment of asthma unless there are also cardiovascular disorders for which these drugs are particularly indicated. Despite the initial promising prospects, all attempts to obtain PGE analogues of therapeutic value as antiasthmatics have proved fruitless. Research into orally active chromone derivatives has proved equally unproductive. On the other hand, certain new inhalatory chromones are decidedly more promising. Specific antagonization of mediators (histamine, prostaglandin, leukotrienes) did not produce the effect hoped for in asthma, but this was foreseeable insofar as the major pathogenic mediators are too vast in number (and no doubt there are still many more to be discovered) to allow one to conceive it possible to achieve a satisfactory therapeutic effect by merely blocking some of them. Inflammation of the bronchial wall is currently considered to be one of the basic pathogenic factors provoking the recurrence of asthma: this is proved indirectly by the potent antiasthmatic effect of corticosteroids which are the most effective anti-inflammatory agents. As regards nonsteroidal anti-inflammatory drugs (NSAID), however, matters are more complicated.(ABSTRACT TRUNCATED AT 250 WORDS)
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D001205:Ascorbic Acid / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy / Q000517:prevention & control; D001991:Bronchitis / Q000188:drug therapy; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002867:Chromones / Q000627:therapeutic use; D004205:Cromolyn Sodium / Q000627:therapeutic use; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy*; D011458:Prostaglandins E / Q000627:therapeutic use
chemical_list: D000305:Adrenal Cortex Hormones; D000316:Adrenergic alpha-Agonists; D002121:Calcium Channel Blockers; D002867:Chromones; D011458:Prostaglandins E; C006312:FPL 55712; D001205:Ascorbic Acid; D004205:Cromolyn Sodium